Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Cholangiocarcinoma 2020: the next horizon in mechanisms and management1110
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention843
Molecular and cellular mechanisms of liver fibrosis and its regression750
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics703
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics638
Advances in immunotherapy for hepatocellular carcinoma596
The four epidemiological stages in the global evolution of inflammatory bowel disease493
Pancreatic cancer stroma: an update on therapeutic targeting strategies445
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma425
Liver regeneration: biological and pathological mechanisms and implications421
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors373
Dietary fibre in gastrointestinal health and disease364
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments343
Advancing the global public health agenda for NAFLD: a consensus statement323
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods319
COVID-19 and liver disease: mechanistic and clinical perspectives260
Global burden of irritable bowel syndrome: trends, predictions and risk factors244
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms243
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2214
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications198
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests184
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications180
Cell death in the gut epithelium and implications for chronic inflammation179
Gut microbiome, big data and machine learning to promote precision medicine for cancer172
The gut microbiome as a modulator of healthy ageing169
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors169
Therapeutic pipeline in nonalcoholic steatohepatitis168
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer166
COVID-19 and the other pandemic: populations made vulnerable by systemic inequity159
AHR in the intestinal microenvironment: safeguarding barrier function154
Cell death in pancreatic cancer: from pathogenesis to therapy152
Role of liver sinusoidal endothelial cells in liver diseases151
From NAFLD to MAFLD: when pathophysiology succeeds150
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis149
Cirrhosis-associated immune dysfunction140
Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD140
Global burden and epidemiology of Barrett oesophagus and oesophageal cancer138
The intestinal barrier, an arbitrator turned provocateur in IBD134
Gastrointestinal biofilms in health and disease127
Enteric glial biology, intercellular signalling and roles in gastrointestinal disease124
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology123
Brain–gut–microbiome interactions in obesity and food addiction120
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance119
Evolving therapeutic landscape of advanced hepatocellular carcinoma118
The role of goblet cells and mucus in intestinal homeostasis118
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment116
Progress towards elimination goals for viral hepatitis114
Modern therapeutic approaches for the treatment of malignant liver tumours114
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity112
Polyploidy in liver development, homeostasis and disease109
Dietary carbohydrates and fats in nonalcoholic fatty liver disease108
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma107
Current and future colorectal cancer screening strategies105
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors101
The evolution and clinical impact of hepatitis B virus genome diversity101
COVID-19 and acute pancreatitis: examining the causality99
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure98
Disorders of the enteric nervous system — a holistic view98
The pancreatic cancer genome revisited96
NAFLD — sounding the alarm on a silent epidemic91
Global epidemiology of cirrhosis — aetiology, trends and predictions90
Nonalcoholic fatty liver disease: another leap forward88
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders87
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology87
Leveraging diet to engineer the gut microbiome86
The role of oral bacteria in inflammatory bowel disease82
Neutrophils as potential therapeutic targets in hepatocellular carcinoma80
Harnessing metabolic dependencies in pancreatic cancers79
The metabolic nature of inflammatory bowel diseases78
Recipient factors in faecal microbiota transplantation: one stool does not fit all73
A risk-stratified approach to colorectal cancer prevention and diagnosis72
Revisiting fibrosis in inflammatory bowel disease: the gut thickens71
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight71
0.10704898834229